Business
TEZSPIRE approved in the US for chronic rhinosinusitis with nasal polyps
WILMINGTON, Del., October 17, 2025--AstraZeneca and Amgen’s TEZSPIRE® (tezepelumab -ekko) has been approved in the US for the add-on maintenance treatment of adult and pediatric patients aged 12 years and older with inadequately controlled chronic rhinosinusitis with nasal polyps (CRSwNP), a complex epithelial-driven inflammatory condition. TEZSPIRE is the first and only biologic that targets thymic stromal lymphopoietin (TSLP) to be approved for CRSwNP.
About this update from Astrazeneca Plc
[{"type":"image","alt":"PAG video","displaySize":"","headline":null,"caption":"PAG video","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":1920,"height":1080,"url":"https://media.zenfs.com/en/business-wire.com/48a82a443ca3da5c9edef32a4beab645"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/szRBYJMPPr3VB.PSjIPhbg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTU0MDtjZj13ZWJw/https://media.zenfs.com/en/business-wire.com/48a82a443ca3da5c9edef32a4beab645","width":960,"height":540},"lightbox":{"url":"https://s.yimg.com/ny/api/res/1.2/E03f2UeuUhCW1CmEk0ZGHw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTI0MDA7aD0xMzUwO2NmPXdlYnA-/https://media.zenfs.com/en/business-wire.com/48a82a443ca3da5c9edef32a4beab645","width":1200,"height":675}},"lazy":false},{"type":"image","alt":"TEZSPIRE B-roll","displaySize":"","headline":null,"caption":"TEZSPIRE B-roll","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":1920,"height":1080,"url":"https://media.zenfs.com/en/business-wire.com/a9a632719040e22ad094cac01d77d25e"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/7jVCmHoAivjjRySFw9WXJA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTU0MDtjZj13ZWJw/https://media.zenfs.com/en/business-wire.com/a9a632719040e22ad094cac01d77d25e","width":960,"height":540},"lightbox":{"url":"https://s.yimg.com/ny/api/res/1.2/vBIhZxIVlQxG_52dDIRjug--/YXBwaWQ9aGlnaGxhbmRlcjt3PTI0MDA7aD0xMzUwO2NmPXdlYnA-/https://media.zenfs.com/en/business-wire.com/a9a632719040e22ad094cac01d77d25e","width":1200,"height":675}}},{"type":"image","alt":"TEZSPIRE Fact Sheet","displaySize":"","headline":null,"caption":"TEZSPIRE Fact Sheet","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":364,"height":480,"url":"https://media.zenfs.com/en/business-wire.com/684c4d9415ee9e04451b31aa72cc90a6"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/eTQv_Hlk3U7Sd1CtG_vFKw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTcwNTtoPTkzMDtjZj13ZWJw/https://media.zenfs.com/en/business-wire.com/684c4d9415ee9e04451b31aa72cc90a6","width":364,"height":480}}},{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":1024,"height":512,"url":"https://media.zenfs.com/en/business-wire.com/52b11bff5269886f38bb608e69cddb9b"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/NYqHCkwz0auu3SbAstzxJA--/YX...